Form 4: IO Biotech CEO Mai-Britt Zocca Acquires 580,000 Stock Options
SEC Form 4 Filing
IO Biotech's CEO, Mai-Britt Zocca, reports the acquisition of 580,000 stock options exercisable for common stock.
Summary
- Mai-Britt Zocca, CEO of IO Biotech, filed a Form 4 disclosing changes in beneficial ownership.
- The report indicates the acquisition of 580,000 stock options on April 2, 2025.
- These options have an exercise price of $1.07.
- The options vest over time, with one-fourth vesting on April 2, 2026, and the remainder vesting monthly thereafter, contingent on continued service.
- The options are subject to accelerated vesting under certain termination scenarios.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about executive compensation.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive compensation and potential alignment of interests.
Stakeholder Impact
- Shareholders may view this as an incentive for the CEO to improve company performance.
- Employees may see this as a sign of the CEO's commitment to the company.
Key Dates
| Date | Description |
|---|---|
| 04/02/2025 | Date of transaction: Acquisition of stock options. |
| 04/02/2026 | Date when one-fourth of the options vest. |
| 04/02/2035 | Expiration date of the stock options. |
| 04/04/2025 | Date of Form 4 filing. |
Keywords
IO Biotech, IOBT, Form 4, Stock Options, Beneficial Ownership, Mai-Britt Zocca, CEO, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.